We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Tech/Science

    RevolKa Ltd. Partners with La Jolla Institute for Immunology to Develop Next-Generation Vaccines

    Jhon Posted on

    RevolKa Ltd., a biotech company specializing in protein engineering, has joined forces with the La Jolla Institute for Immunology (LJI) to collaborate on creating antigens for next-generation vaccines. The aim of this partnership is to address unmet medical needs in the field of infectious diseases.

    RevolKa’s innovative technology platform, aiProtein, combines protein engineering with artificial intelligence (AI) to predict sequences for evolved protein function. This technology, integrated with LJI’s expertise in immunology, is set to revolutionize the development of vaccines.

    While the financial details of the collaboration have not been disclosed, the strategic alliance between RevolKa and LJI marks a significant step towards advancing vaccine research and development.

    Stay tuned for more updates on this groundbreaking partnership in the biotech and immunology sectors.

    Tagged:

    LEAVE A RESPONSE

    Your email address will not be published. Required fields are marked *

    Jhon
    View all posts

    You Might Also Like